Relationships among nortriptyline, 10-OH(E)nortriptyline, and 10-OH(Z)nortriptyline steady-state plasma levels and nortriptyline dosage

Brian J. Lukey, David R. Jones, Jesse H. Wright, Harrell E. Hurst

Research output: Contribution to journalArticle

Abstract

The postulated therapeutic activity of nortriptyline metabolites has prompted investigation of dosage adjustments based on plasma levels of nortriptyline (NT) and its metabolites. The method assumes that metabolite concentrations vary independently of nortriptyline concentrations among patients. This study tests that assumption and investigates different means of obtaining metabolite concentrations. Forty-two psychiatric inpatients were divided into three maintenance dose groups: 50,100, and 150 mg NT/day. After a 28-day study for each inpatient, steady-state plasma concentrations for days 14,18, 21, 25, and 28 were determined. Concentrations were averaged for each patient. Nortriptyline concentrations did not correlate well with corresponding 10-OH(E)nortriptyline (p > 0.05) or 10-OH(Z)nortriptyline concentrations (r = 0.31, p <0.05). Concentrations of 10-OH(E)nortriptyline did not correlate well with corresponding 10-OH(Z)nortriptyline concentrations (r2 = 0.236, p <0.05). Neither dose/body weight nor obesity were good predictors of individual concentrations of nortriptyline, 10-OH(E)nortriptyline, or 10-OH(Z)nortriptyline or even the sum of the three. In conclusion, optimal drug therapy may involve dosage adjustments according to the combined plasma levels of nortriptyline and metabolites. Assurance of obtaining certain plasma concentrations requires plasma level monitoring.

Original languageEnglish (US)
Pages (from-to)221-227
Number of pages7
JournalTherapeutic Drug Monitoring
Volume11
Issue number3
StatePublished - 1989
Externally publishedYes

Fingerprint

Nortriptyline
Plasmas
Metabolites
Inpatients
Drug therapy

Keywords

  • 10-OH(E)nortriptyline
  • 10-OH(Z)nortriptyline
  • Metabolites
  • Nortriptyline
  • Plasma concentration

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Health, Toxicology and Mutagenesis
  • Public Health, Environmental and Occupational Health
  • Toxicology

Cite this

Relationships among nortriptyline, 10-OH(E)nortriptyline, and 10-OH(Z)nortriptyline steady-state plasma levels and nortriptyline dosage. / Lukey, Brian J.; Jones, David R.; Wright, Jesse H.; Hurst, Harrell E.

In: Therapeutic Drug Monitoring, Vol. 11, No. 3, 1989, p. 221-227.

Research output: Contribution to journalArticle

Lukey, Brian J. ; Jones, David R. ; Wright, Jesse H. ; Hurst, Harrell E. / Relationships among nortriptyline, 10-OH(E)nortriptyline, and 10-OH(Z)nortriptyline steady-state plasma levels and nortriptyline dosage. In: Therapeutic Drug Monitoring. 1989 ; Vol. 11, No. 3. pp. 221-227.
@article{ecb220c86b1c4e3684708ba7ec795b26,
title = "Relationships among nortriptyline, 10-OH(E)nortriptyline, and 10-OH(Z)nortriptyline steady-state plasma levels and nortriptyline dosage",
abstract = "The postulated therapeutic activity of nortriptyline metabolites has prompted investigation of dosage adjustments based on plasma levels of nortriptyline (NT) and its metabolites. The method assumes that metabolite concentrations vary independently of nortriptyline concentrations among patients. This study tests that assumption and investigates different means of obtaining metabolite concentrations. Forty-two psychiatric inpatients were divided into three maintenance dose groups: 50,100, and 150 mg NT/day. After a 28-day study for each inpatient, steady-state plasma concentrations for days 14,18, 21, 25, and 28 were determined. Concentrations were averaged for each patient. Nortriptyline concentrations did not correlate well with corresponding 10-OH(E)nortriptyline (p > 0.05) or 10-OH(Z)nortriptyline concentrations (r = 0.31, p <0.05). Concentrations of 10-OH(E)nortriptyline did not correlate well with corresponding 10-OH(Z)nortriptyline concentrations (r2 = 0.236, p <0.05). Neither dose/body weight nor obesity were good predictors of individual concentrations of nortriptyline, 10-OH(E)nortriptyline, or 10-OH(Z)nortriptyline or even the sum of the three. In conclusion, optimal drug therapy may involve dosage adjustments according to the combined plasma levels of nortriptyline and metabolites. Assurance of obtaining certain plasma concentrations requires plasma level monitoring.",
keywords = "10-OH(E)nortriptyline, 10-OH(Z)nortriptyline, Metabolites, Nortriptyline, Plasma concentration",
author = "Lukey, {Brian J.} and Jones, {David R.} and Wright, {Jesse H.} and Hurst, {Harrell E.}",
year = "1989",
language = "English (US)",
volume = "11",
pages = "221--227",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Relationships among nortriptyline, 10-OH(E)nortriptyline, and 10-OH(Z)nortriptyline steady-state plasma levels and nortriptyline dosage

AU - Lukey, Brian J.

AU - Jones, David R.

AU - Wright, Jesse H.

AU - Hurst, Harrell E.

PY - 1989

Y1 - 1989

N2 - The postulated therapeutic activity of nortriptyline metabolites has prompted investigation of dosage adjustments based on plasma levels of nortriptyline (NT) and its metabolites. The method assumes that metabolite concentrations vary independently of nortriptyline concentrations among patients. This study tests that assumption and investigates different means of obtaining metabolite concentrations. Forty-two psychiatric inpatients were divided into three maintenance dose groups: 50,100, and 150 mg NT/day. After a 28-day study for each inpatient, steady-state plasma concentrations for days 14,18, 21, 25, and 28 were determined. Concentrations were averaged for each patient. Nortriptyline concentrations did not correlate well with corresponding 10-OH(E)nortriptyline (p > 0.05) or 10-OH(Z)nortriptyline concentrations (r = 0.31, p <0.05). Concentrations of 10-OH(E)nortriptyline did not correlate well with corresponding 10-OH(Z)nortriptyline concentrations (r2 = 0.236, p <0.05). Neither dose/body weight nor obesity were good predictors of individual concentrations of nortriptyline, 10-OH(E)nortriptyline, or 10-OH(Z)nortriptyline or even the sum of the three. In conclusion, optimal drug therapy may involve dosage adjustments according to the combined plasma levels of nortriptyline and metabolites. Assurance of obtaining certain plasma concentrations requires plasma level monitoring.

AB - The postulated therapeutic activity of nortriptyline metabolites has prompted investigation of dosage adjustments based on plasma levels of nortriptyline (NT) and its metabolites. The method assumes that metabolite concentrations vary independently of nortriptyline concentrations among patients. This study tests that assumption and investigates different means of obtaining metabolite concentrations. Forty-two psychiatric inpatients were divided into three maintenance dose groups: 50,100, and 150 mg NT/day. After a 28-day study for each inpatient, steady-state plasma concentrations for days 14,18, 21, 25, and 28 were determined. Concentrations were averaged for each patient. Nortriptyline concentrations did not correlate well with corresponding 10-OH(E)nortriptyline (p > 0.05) or 10-OH(Z)nortriptyline concentrations (r = 0.31, p <0.05). Concentrations of 10-OH(E)nortriptyline did not correlate well with corresponding 10-OH(Z)nortriptyline concentrations (r2 = 0.236, p <0.05). Neither dose/body weight nor obesity were good predictors of individual concentrations of nortriptyline, 10-OH(E)nortriptyline, or 10-OH(Z)nortriptyline or even the sum of the three. In conclusion, optimal drug therapy may involve dosage adjustments according to the combined plasma levels of nortriptyline and metabolites. Assurance of obtaining certain plasma concentrations requires plasma level monitoring.

KW - 10-OH(E)nortriptyline

KW - 10-OH(Z)nortriptyline

KW - Metabolites

KW - Nortriptyline

KW - Plasma concentration

UR - http://www.scopus.com/inward/record.url?scp=0024556243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024556243&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 221

EP - 227

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 3

ER -